No Data
12 Health Care Stocks Moving In Friday's After-Market Session
Purple Biotech Shares Are Trading Lower. The Company Presented New Data Regarding Its Tri-specific Antibody Platform CAPTN-3.
Purple Biotech Unveils CAPTN-3 Cancer Therapy
Purple Biotech Regains Nasdaq Compliance
HC Wainwright & Co. Maintains Buy on Purple Biotech, Adjusts Price Target To $33 (1-20 Reverse Stock Split)
H.C. Wainwright Maintains Purple Biotech(PPBT.US) With Buy Rating, Cuts Target Price to $33
H.C. Wainwright analyst Emily Bodnar maintains $Purple Biotech(PPBT.US)$ with a buy rating, and adjusts the target price from $200 to $33.According to TipRanks data, the analyst has a success rate
No Data
No Data